The Atlas Venture partner, reflecting on two decades of investing, advises against rushing into IPOs and notes luck’s role in ...

Key milestone achieved as Company advances clinical program to full approval trial of ateganosine sequenced with a checkpoint inhibitor in ...

So, the natural question for Vir Biotechnology (NASDAQ:VIR) shareholders is whether they should be concerned by its rate of cash burn. In this article, we define cash burn as its annual (negative) ...

MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on ...

The coming era of biosecurity will demand a broader and more adaptive approach as AI, powerful biological engineering ...

Researchers from ETH Zurich have succeeded in introducing large quantities of unnatural amino acids into bacteria, enabling ...

Merck’s Keytruda, the category-defining CPI, reported $29.5 billion in revenue in 2024, with NSCLC representing an estimated 30% of its total sales. Keytruda is expected to approach $35 billion by ...

Like our stuff? Consider supporting us! 𝗧𝗵𝗲 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗻𝗶𝘁𝘁𝘆-𝗴𝗿𝗶𝘁𝘁𝘆: -Auffarth B (2013).

Provisions on research security, grant policies, indirect cost rates, and more are packed into the latest version of the NDAA ...

Associate Professor Ben Sullivan explores the connections between local meadows and the health of the environment ...

How a new recommendation on hepatitis B vaccination could add confusion for families and limit protection against other ...

Powered by menopausal thinning, stress, TikTok ingredient literacy and the rise of beautytech and algorithmic diagnostics, ...